SG11202111109UA - Biparatopic fr-alpha antibodies and immunoconjugates - Google Patents
Biparatopic fr-alpha antibodies and immunoconjugatesInfo
- Publication number
- SG11202111109UA SG11202111109UA SG11202111109UA SG11202111109UA SG11202111109UA SG 11202111109U A SG11202111109U A SG 11202111109UA SG 11202111109U A SG11202111109U A SG 11202111109UA SG 11202111109U A SG11202111109U A SG 11202111109UA SG 11202111109U A SG11202111109U A SG 11202111109UA
- Authority
- SG
- Singapore
- Prior art keywords
- biparatopic
- immunoconjugates
- alpha antibodies
- antibodies
- alpha
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962840297P | 2019-04-29 | 2019-04-29 | |
US201962879864P | 2019-07-29 | 2019-07-29 | |
PCT/US2020/030245 WO2020223221A1 (en) | 2019-04-29 | 2020-04-28 | Biparatopic fr-alpha antibodies and immunoconjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111109UA true SG11202111109UA (en) | 2021-11-29 |
Family
ID=73028723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111109UA SG11202111109UA (en) | 2019-04-29 | 2020-04-28 | Biparatopic fr-alpha antibodies and immunoconjugates |
Country Status (12)
Country | Link |
---|---|
US (3) | US11396543B2 (zh) |
EP (1) | EP3962935A4 (zh) |
JP (1) | JP2022530524A (zh) |
KR (1) | KR20220004687A (zh) |
CN (1) | CN114222756A (zh) |
AU (1) | AU2020265568A1 (zh) |
CA (1) | CA3138272A1 (zh) |
IL (1) | IL287451A (zh) |
MA (1) | MA55818A (zh) |
SG (1) | SG11202111109UA (zh) |
TW (1) | TW202100557A (zh) |
WO (1) | WO2020223221A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2911499A1 (en) * | 2013-05-14 | 2014-11-20 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
HUE055856T2 (hu) | 2013-08-30 | 2021-12-28 | Immunogen Inc | Antitestek és vizsgálatok a folsavreceptor 1 kimutatására |
CA3138272A1 (en) * | 2019-04-29 | 2020-11-05 | Immunogen, Inc. | Biparatopic fr-alpha antibodies and immunoconjugates |
EP4347661A1 (en) * | 2021-06-04 | 2024-04-10 | ImmunoGen, Inc. | Treatment of cancer in patients with soluble fr-alpha |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
TW202409080A (zh) * | 2022-07-26 | 2024-03-01 | 美商沙塔克實驗室股份有限公司 | 用於治療卵巢癌之組合療法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3101034A1 (en) | 2004-02-12 | 2016-12-07 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
EP1879922A2 (en) | 2005-04-22 | 2008-01-23 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
EP3196212B1 (en) | 2010-02-24 | 2020-06-03 | ImmunoGen, Inc. | Immunoconjugates comprising a folate receptor 1 antibody |
WO2012061759A2 (en) | 2010-11-05 | 2012-05-10 | Morphotek Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
EA028805B1 (ru) | 2011-04-01 | 2018-01-31 | Иммьюноджен, Инк. | Способы повышения эффективности folr1 терапии рака |
WO2012138749A1 (en) | 2011-04-04 | 2012-10-11 | Immunogen, Inc. | Methods for decreasing ocular toxicity of antibody drug conjugates |
KR20200079565A (ko) | 2012-08-31 | 2020-07-03 | 이뮤노젠 아이엔씨 | 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트 |
CA2911499A1 (en) | 2013-05-14 | 2014-11-20 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
HUE055856T2 (hu) | 2013-08-30 | 2021-12-28 | Immunogen Inc | Antitestek és vizsgálatok a folsavreceptor 1 kimutatására |
KR102115217B1 (ko) | 2013-10-08 | 2020-05-26 | 이뮤노젠 아이엔씨 | 항-folr1 면역접합체 투여 레지멘 |
EP3153178A4 (en) | 2014-06-06 | 2017-12-20 | Kyowa Hakko Kirin Co., Ltd. | Method for treating cancer patients using folr1 targeted drug and antifolate, and drug |
SG11201701328XA (en) | 2014-09-02 | 2017-03-30 | Immunogen Inc | Methods for formulating antibody drug conjugate compositions |
AU2016323968B2 (en) | 2015-09-17 | 2023-07-06 | Immunogen, Inc. | Therapeutic combinations comprising anti-FOLR1 immunoconjugates |
IL298414A (en) * | 2017-02-28 | 2023-01-01 | Immunogen Inc | History of methanosinoids with peptide linkers and their conjugates |
GB201707864D0 (en) | 2017-05-16 | 2017-06-28 | Inst Of Cancer Research: Royal Cancer Hospital | Platinum-reistant cancer treatment |
AU2018328187A1 (en) | 2017-09-05 | 2020-03-26 | Immunogen, Inc. | Methods for detection of folate receptor 1 in a patient sample |
CN111163804A (zh) | 2017-09-22 | 2020-05-15 | 伊缪诺金公司 | 使用阳离子交换色谱法分离三轻链抗体 |
TW201934187A (zh) | 2018-01-12 | 2019-09-01 | 美商免疫遺傳股份有限公司 | 抗體藥物結合、純化、及調配之方法 |
CA3138272A1 (en) | 2019-04-29 | 2020-11-05 | Immunogen, Inc. | Biparatopic fr-alpha antibodies and immunoconjugates |
EP4347661A1 (en) * | 2021-06-04 | 2024-04-10 | ImmunoGen, Inc. | Treatment of cancer in patients with soluble fr-alpha |
-
2020
- 2020-04-28 CA CA3138272A patent/CA3138272A1/en active Pending
- 2020-04-28 US US16/860,822 patent/US11396543B2/en active Active
- 2020-04-28 CN CN202080037442.7A patent/CN114222756A/zh active Pending
- 2020-04-28 MA MA055818A patent/MA55818A/fr unknown
- 2020-04-28 KR KR1020217037919A patent/KR20220004687A/ko unknown
- 2020-04-28 TW TW109114175A patent/TW202100557A/zh unknown
- 2020-04-28 JP JP2021564298A patent/JP2022530524A/ja active Pending
- 2020-04-28 AU AU2020265568A patent/AU2020265568A1/en active Pending
- 2020-04-28 EP EP20798751.2A patent/EP3962935A4/en active Pending
- 2020-04-28 WO PCT/US2020/030245 patent/WO2020223221A1/en unknown
- 2020-04-28 SG SG11202111109UA patent/SG11202111109UA/en unknown
-
2021
- 2021-10-20 IL IL287451A patent/IL287451A/en unknown
-
2022
- 2022-06-10 US US17/838,016 patent/US11834498B2/en active Active
-
2023
- 2023-10-24 US US18/493,623 patent/US20240182560A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020265568A1 (en) | 2021-11-04 |
US20240182560A1 (en) | 2024-06-06 |
US20230085779A1 (en) | 2023-03-23 |
CN114222756A (zh) | 2022-03-22 |
MA55818A (fr) | 2022-03-16 |
US11396543B2 (en) | 2022-07-26 |
KR20220004687A (ko) | 2022-01-11 |
US11834498B2 (en) | 2023-12-05 |
IL287451A (en) | 2021-12-01 |
US20200362029A1 (en) | 2020-11-19 |
WO2020223221A1 (en) | 2020-11-05 |
CA3138272A1 (en) | 2020-11-05 |
TW202100557A (zh) | 2021-01-01 |
JP2022530524A (ja) | 2022-06-29 |
EP3962935A4 (en) | 2023-05-31 |
EP3962935A1 (en) | 2022-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275737A (en) | Variant antibodies against TIGIT | |
IL276950A (en) | Anti-CD73 antibodies and uses thereof | |
IL278846A (en) | Anti-CD3 antibodies and uses thereof | |
EP3604338A4 (en) | ANTI-OX40 ANTIBODIES AND CORRESPONDING USE | |
IL282968A (en) | Anti-NKG2A antibodies and their use | |
IL287451A (en) | Biparatopic fr-alpha antibodies and immunoconjugates | |
ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
SG11202104240TA (en) | Cll1-targeting antibody and application thereof | |
IL275826A (en) | Anti-mct1 antibodies and their uses | |
IL289585A (en) | DLL3-targeted antibodies and uses thereof | |
IL281297A (en) | Anti-NPR1 antibodies and uses thereof | |
IL288998A (en) | Anti-mesothelin antibodies and their immunoconjugates | |
EP3625262A4 (en) | ANTI-FOLR1 IMMUNOCONJUGATES AND ANTI-PD-1 ANTIBODY COMBINATIONS | |
IL277330A (en) | Anti-IL-27 antibodies and uses thereof | |
IL287690A (en) | Antibodies against hvem and their use | |
EP4032904A4 (en) | ANTI-ALPHA HEMOLYSIN ANTIBODIES AND USE THEREOF | |
SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
IL282708A (en) | Anti-tim-3 antibodies and their use | |
IL282707A (en) | Anti-tim-3 antibodies and their use | |
IL280321A (en) | Antibodies against CXCR2 and their uses | |
IL289656A (en) | Anti-tigit antibodies and their application | |
IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
IL280281A (en) | Anti-CD40 antibodies and uses thereof | |
IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
IL281202A (en) | Anti-TNFRSF9 antibodies and uses thereof |